In Part I, we discussed the nature of nanotechnology and the promise that it holds for biotechnology—why the two disciplines seem like such a natural fit for each other. Here, in Part II, we get specific: what’s being done at the moment, which nanotech drugs are already approved and which ones are in the pipeline...
